2024
Coexistent Eosinophilic Esophagitis and Dysplastic Barrett's Esophagus With Rapid Eosinophilic Infiltration of Neosquamous Mucosa After Radiofrequency Ablation
Ameyaw P, Parsons D, Mahmoud A, Marie R, Nagar A, Aslanian H. Coexistent Eosinophilic Esophagitis and Dysplastic Barrett's Esophagus With Rapid Eosinophilic Infiltration of Neosquamous Mucosa After Radiofrequency Ablation. ACG Case Reports Journal 2024, 11: e01488. PMID: 39221230, PMCID: PMC11361630, DOI: 10.14309/crj.0000000000001488.Peer-Reviewed Original ResearchBarrett's esophagusRadiofrequency ablationDysplastic BEEosinophilic esophagitisOutcomes of radiofrequency ablationNeosquamous mucosaAssociation of gastroesophageal reflux diseaseEndoscopic eradication therapyDysplastic Barrett's esophagusGastroesophageal reflux diseaseEradication therapyEosinophil infiltrationReflux diseasePatientsEsophagealEoEEsophagusMucosaAblationRadiofrequencyPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXScoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
Rüschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, Martini M, Cheng L, Tretiakova M, Mitchell C, Anders R, Robert M, Fahy D, Pyle M, Le Q, Yu L, Glass B, Baxi V, Babadjanova Z, Pratt J, Brutus S, Karasarides M, Hartmann A. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Virchows Archiv 2024, 484: 597-608. PMID: 38570364, DOI: 10.1007/s00428-024-03795-8.Peer-Reviewed Original ResearchConceptsPD-L1 expressionImmune checkpoint inhibitorsPD-L1Tumor cellsAssess programmed death ligand 1Assessment of PD-L1 expressionScoring of PD-L1 expressionInternational multi-institutional studyPD-L1 expression analysisFood and Drug Administration-approvedPD-L1 stainingDeath-ligand 1Drug Administration-approvedMulti-institutional studyCheckpoint inhibitorsUrothelial carcinomaPathological assessmentBiomarker expressionInterobserver variabilityLigand 1Cancer treatmentExpert pathologistsClinical settingMultinational studyPositive rateOpportunities for Improving Biopsy and Non–Biopsy-Based Diagnosis of Celiac Disease
Robert M, Ciacci C, Lebwohl B. Opportunities for Improving Biopsy and Non–Biopsy-Based Diagnosis of Celiac Disease. Gastroenterology 2024, 167: 79-89. PMID: 38302007, DOI: 10.1053/j.gastro.2024.01.031.Peer-Reviewed Original Research
2023
Guidelines for best practices in monitoring established coeliac disease in adult patients
Elli L, Leffler D, Cellier C, Lebwohl B, Ciacci C, Schumann M, Lundin K, Chetcuti Zammit S, Sidhu R, Roncoroni L, Bai J, Lee A, Dennis M, Robert M, Rostami K, Khater S, Comino I, Cebolla A, Branchi F, Verdu E, Stefanolo J, Wolf R, Bergman-Golden S, Trott N, Scudeller L, Zingone F, Scaramella L, Sanders D. Guidelines for best practices in monitoring established coeliac disease in adult patients. Nature Reviews Gastroenterology & Hepatology 2023, 21: 198-215. PMID: 38110546, DOI: 10.1038/s41575-023-00872-2.Peer-Reviewed Original ResearchConceptsCoeliac diseaseLevel of evidenceLife-long gluten-free dietGluten-free dietMucosal atrophyAdult patientsCirculating autoantibodiesFollow-upGenetic predispositionImmunological diseasesRecommendations AssessmentMonitoring patientsClinical guidelinesEvidence levelPatientsConsumption of glutenDiagnosisDiseaseGuidelinesScientific societiesCeDAutoantibodiesGastroenterologistsAtrophyWATS3D: An Interobserver Study of Barrett's Esophagus–Associated Dysplasia Among Gastrointestinal Pathologists
Patil D, Goldblum J, Lauwers G, Lewis J, Robert M, Singer M, Odze R. WATS3D: An Interobserver Study of Barrett's Esophagus–Associated Dysplasia Among Gastrointestinal Pathologists. Clinical And Translational Gastroenterology 2023, 15: e00661. PMID: 38088399, PMCID: PMC10887448, DOI: 10.14309/ctg.0000000000000661.Peer-Reviewed Original ResearchConceptsBarrett's esophagusGI pathologistsCell blocksWide-area transepithelial samplingDetection rate of dysplasiaBE-associated dysplasiaRate of dysplasiaKappa valuesDetection of neoplasiaGastrointestinal (GILiquid cytologyEvaluate digital imagesSmear specimensGastrointestinal pathologistsInterobserver variabilityIndividual diagnostic categoriesStudy pathologistsInterobserver studyDysplasiaPathologistsCellular fociComputer-assisted analysisDiagnostic categoriesDetection rateTraining sessionsRare cases of colonic schwannomas
Gazivoda V, Wang D, Siddique M, Zeng J, Robert M, Pantel H, Mongiu A. Rare cases of colonic schwannomas. Journal Of Surgical Case Reports 2023, 2023: rjac438. PMID: 38163055, PMCID: PMC10757069, DOI: 10.1093/jscr/rjac438.Peer-Reviewed Original ResearchSpindle cell neoplasmTransverse colonMesenchymal tumorsCell neoplasmsProximal transverse colonSegmental transverse colectomyRare spindle cell tumorSpindle cell tumorsColonic schwannomaJumbo forcepsTransverse colectomyPrimary anastomosisSurveillance colonoscopyMucosal biopsiesSubmucosal lesionsColon massElderly malesSubmucosal resectionCell tumorsDeep biopsyElderly femalesSurgical decisionNinth caseRare caseCT scanClinical Data Do Not Reliably Predict Duodenal Histology at Follow-up in Celiac Disease
Patel N, Leffler D, Al-Toma A, Mulder C, Elli L, Gan G, Patil P, Atsawarungruangkit A, Kuijpers K, Del Gobbo A, Goldsmith J, Hintze Z, Pacheco M, Vieth M, Melcher B, Salomao M, Pai R, Hart J, Olivas A, Naini B, Meyerson C, Choi W, Kakar S, Westerhoff M, Cheng J, Gopal P, Hammer S, Prats M, Bronner M, Robert M. Clinical Data Do Not Reliably Predict Duodenal Histology at Follow-up in Celiac Disease. The American Journal Of Surgical Pathology 2023, 48: 212-220. PMID: 37994653, DOI: 10.1097/pas.0000000000002150.Peer-Reviewed Original ResearchIntraepithelial lymphocytesCeliac diseaseClinical dataMarsh scoreMucosal recoveryVillous bluntingDuodenal biopsiesMucosal injuryDiet adherenceGluten-free diet adherenceComplete histologic remissionPersistent mucosal injuryMinority of patientsCeliac disease patientsDuodenal histologyHistologic remissionPathologists' awarenessMucosal statusMucosal healingGastrointestinal pathologistsDisease patientsFollow-upPatient managementEligibility criteriaPatientsStandardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study
Lebwohl B, Ma C, Lagana S, Pai R, Baker K, Zayadi A, Hogan M, Bouma G, Cellier C, Goldsmith J, Lundin K, Pinto-Sanchez M, Robert M, Rubio-Tapia A, Sanders D, Schaeffer D, Semrad C, Silvester J, Verdú E, Verma R, Wu T, Feagan B, Crowley E, Jairath V, Murray J. Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study. Gastroenterology 2023, 166: 88-102. PMID: 37704112, DOI: 10.1053/j.gastro.2023.08.051.Peer-Reviewed Original ResearchConceptsRandomized controlled trialsSecondary patient-reported outcome measuresOutcome measuresRandomized controlled trial designPatient-reported outcome measuresControlled trialsGluten challengeStandard Randomized Controlled TrialPatient-reported outcomesGluten-free dietReversal of histological changesMethods studyCeliac diseaseEligibility criteriaHistological end pointsPrevention of relapseEffective pharmacological optionsAppropriate studiesTrial outcomesExclusion criteriaClinical trial designTrial designTreatment of celiac diseasePediatric patientsPharmacological optionsMKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention
Qiu B, Lawan A, Xirouchaki C, Yi J, Robert M, Zhang L, Brown W, Fernández-Hernando C, Yang X, Tiganis T, Bennett A. MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention. Nature Communications 2023, 14: 5405. PMID: 37669951, PMCID: PMC10480499, DOI: 10.1038/s41467-023-41145-5.Peer-Reviewed Original ResearchScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Mann J, Lucca L, Austin M, Merkin R, Robert M, Al Bawardy B, Raddassi K, Aizenbud L, Joshi N, Hafler D, Abraham C, Herold K, Kluger H. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2023, 11: e007358. PMID: 37586769, PMCID: PMC10432652, DOI: 10.1136/jitc-2023-007358.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsT cell subsetsCheckpoint inhibitorsImmune environmentImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisPeripheral immune environmentsStages of colitisTreatment of colitisMerkel cell carcinomaT cell populationsPeripheral blood samplesCourse of progressionT cell receptorMultiple tumor typesAlternative cancer therapyCommon toxicitiesICI colitisTreatment discontinuationAdverse eventsBiologic therapyImmune suppressionCell carcinomaColitisBlood samplesCholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P, Robert M, Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Archives Of Pathology & Laboratory Medicine 2023, 148: 359-370. PMID: 37327187, DOI: 10.5858/arpa.2022-0537-ra.Peer-Reviewed Original ResearchConceptsDiagnosis of cholangiocarcinomaImmune checkpoint inhibitorsAdvanced tumor stageHeterogeneous tumor groupTumor growth patternEra of precision medicineTherapeutic decision-makingEvaluation of cholangiocarcinomaExtrahepatic biliary treeGenetic testing methodologiesSite of originCheckpoint inhibitorsTumor inaccessibilityMetastatic adenocarcinomaPeriductal infiltrationTumor stageIntraductal tumorClinical presentationDifferentiate cholangiocarcinomaImmunohistochemical profileTumor groupExtrahepatic cholangiocarcinomaTargeted therapyPathological diagnosisIntrahepatic cholangiocarcinomaErratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154]
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsar I, Kumar G, Karasarides M, Anders R. Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154]. Modern Pathology 2023, 36: 100238. PMID: 37327723, DOI: 10.1016/j.modpat.2023.100238.Peer-Reviewed Original ResearchSa1935 STRATEGIES FOR IMPROVING INTER-READER VARIABILITY OF VILLUS HEIGHT AND CRYPT DEPTH MEASUREMENTS ACROSS DIFFERENT INSTITUTIONS
Maxwell J, Isola J, Välimäki A, Leffler D, Raunig D, Cordover D, Murray J, Robert M, Chen Z, Lei Q, Wu T, Smithson G. Sa1935 STRATEGIES FOR IMPROVING INTER-READER VARIABILITY OF VILLUS HEIGHT AND CRYPT DEPTH MEASUREMENTS ACROSS DIFFERENT INSTITUTIONS. Gastroenterology 2023, 164: s-487. DOI: 10.1016/s0016-5085(23)02132-7.Peer-Reviewed Original Research856 WATS3D INTEROBSERVER STUDY SHOWS EXCELLENT REPRODUCIBILITY AMONG ACADEMIC GI PATHOLOGISTS
Odze R, Goldblum J, Lauwers G, Lewis J, Patil D, Robert M, Singer M. 856 WATS3D INTEROBSERVER STUDY SHOWS EXCELLENT REPRODUCIBILITY AMONG ACADEMIC GI PATHOLOGISTS. Gastroenterology 2023, 164: s-187. DOI: 10.1016/s0016-5085(23)01408-7.Peer-Reviewed Original ResearchIdiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis
Rozner R, Gisriel S, Damianos J, Grimshaw A, Rizwan R, Nawaz A, Chan K, Wan D, Pantel H, Bhutta A, Fenster M, Brandt L, Barbieri A, Robert M, Feuerstadt P, Li D. Idiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis. Journal Of Gastroenterology And Hepatology 2023, 38: 1040-1046. PMID: 37086041, DOI: 10.1111/jgh.16193.Peer-Reviewed Original ResearchConceptsIdiopathic myointimal hyperplasiaColonic ischemiaMesenteric veinRectal bleedingRectal involvementMyointimal hyperplasiaSystematic reviewYounger ageMultivariate logistic regression analysisCurative surgical resectionInferior mesenteric veinPre-surgical identificationLogistic regression analysisRegression analysisIschemic colitisAbdominal painMucosal ulcerationEndoscopic findingsSelect patientsSurgical resectionUncommon causeDiagnostic delaySurgical treatmentClinical featuresHospital recordsHigh Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic reviewPrecision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?
Farrell J, Robert M, Lacy J. Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity? Clinical Gastroenterology And Hepatology 2023, 21: 2740-2742. PMID: 36640803, DOI: 10.1016/j.cgh.2022.12.033.Peer-Reviewed Original Research
2022
Mitochondrial fitness and cancer risk
Kossenkov AV, Milcarek A, Notta F, Jang GH, Wilson JM, Gallinger S, Zhou DC, Ding L, Ghosh JC, Perego M, Morotti A, Locatelli M, Robert ME, Vaira V, Altieri DC. Mitochondrial fitness and cancer risk. PLOS ONE 2022, 17: e0273520. PMID: 36223343, PMCID: PMC9555630, DOI: 10.1371/journal.pone.0273520.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSenescence-Associated Secretory PhenotypeIndependent patient cohortsPoor patient outcomesAggressive disease variantFolfirinox failureLocal inflammationPatient cohortDuctal adenocarcinomaPatient outcomesPatient riskMultiple malignanciesCancer riskMitochondrial fitnessSecretory phenotypeGene signatureHallmarks of cancerMetastatic propensityNormal tissuesHuman tumorsInterferon SignalingTumorsInner membrane mitochondrial proteinMalignancyMolecular signaturesOpen-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
Hussain N, Robert M, Al-Bawardy B. Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Reports Journal 2022, 9: e00882. PMID: 36237281, PMCID: PMC9553371, DOI: 10.14309/crj.0000000000000882.Peer-Reviewed Original Research